Autoantibody production in anti-TNF-alpha-treated patients (Q36958337)

17 August 2017

1 reference

title

Autoantibody production in anti-TNF-alpha-treated patients (English)

1 reference

Francesca Romana Spinelli

17 August 2017

0 references

1 reference

object named as

Francesca Romana Spinelli

3

0 references

Cristiano Alessandri

object named as

Cristiano Alessandri

1

0 references

Guido Valesini

7

object named as

Guido Valesini

1 reference

17 August 2017

Rossana Scrivo

2

1 reference

17 August 2017

Fulvia Ceccarelli

4

1 reference

17 August 2017

Leonardo Magrini

5

1 reference

17 August 2017

Roberta Priori

6

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Annals of the New York Academy of Sciences

17 August 2017

1 reference

17 August 2017

1110

1 reference

17 August 2017

319-329

1 reference

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

17 August 2017

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Autoimmune aspects of cytokine and anticytokine therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

The long-term efficacy and safety of new biological therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Development of new-onset psoriasis while on anti-TNFalpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Adalimumab in the therapy of uveitis in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Does etanercept induce uveitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

T-Cell Function and Migration — Two Sides of the Same Coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Development of additional autoimmune diseases in a population of patients with primary Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

The clearance of apoptotic cells: implications for autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Structure and function of the pentraxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.034

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1423.034

1 reference

17 August 2017

1 reference